Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI343 in Advanced Pancreatic Cancer
NCT07066098Phase 3Recruiting
- Sponsor
- Innovent Biologics
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of arcotatug tavatecan in pancreatic cancer (PC), sponsored by Innovent Biologics. Started Jul 2025; status: recruiting.
02
Drugs
arcotatug tavatecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07066098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07066098.